DK2753352T4 - Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf - Google Patents

Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf Download PDF

Info

Publication number
DK2753352T4
DK2753352T4 DK11769799.5T DK11769799T DK2753352T4 DK 2753352 T4 DK2753352 T4 DK 2753352T4 DK 11769799 T DK11769799 T DK 11769799T DK 2753352 T4 DK2753352 T4 DK 2753352T4
Authority
DK
Denmark
Prior art keywords
toxin
difficile
proteins
isolated polypeptide
polypeptide
Prior art date
Application number
DK11769799.5T
Other languages
English (en)
Other versions
DK2753352T3 (da
DK2753352T5 (da
Inventor
Larry Ellingsworth
David Flyer
Jing-Hui Tian
Steven Fuhrmann
Stefanie Kluepfel-Stahl
Gregory Glenn
Kerstin Westritschnig
Original Assignee
Valneva Austria Gmbh
Valneva Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799993&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2753352(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh, Valneva Usa Inc filed Critical Valneva Austria Gmbh
Publication of DK2753352T3 publication Critical patent/DK2753352T3/da
Application granted granted Critical
Publication of DK2753352T5 publication Critical patent/DK2753352T5/da
Publication of DK2753352T4 publication Critical patent/DK2753352T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11769799.5T 2010-09-03 2011-09-05 Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf DK2753352T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37989210P 2010-09-03 2010-09-03
PCT/EP2011/065304 WO2012028741A1 (en) 2010-09-03 2011-09-05 Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Publications (3)

Publication Number Publication Date
DK2753352T3 DK2753352T3 (da) 2017-03-06
DK2753352T5 DK2753352T5 (da) 2017-05-01
DK2753352T4 true DK2753352T4 (da) 2022-09-12

Family

ID=44799993

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11769799.5T DK2753352T4 (da) 2010-09-03 2011-09-05 Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf

Country Status (22)

Country Link
US (6) US9598472B2 (da)
EP (3) EP3167899B1 (da)
JP (1) JP6121421B2 (da)
KR (1) KR101907434B1 (da)
CN (1) CN103957931B (da)
AU (1) AU2011298306B2 (da)
BR (1) BR112014004896B1 (da)
CA (1) CA2873272C (da)
CY (1) CY1118664T1 (da)
DK (1) DK2753352T4 (da)
ES (2) ES2867375T3 (da)
HK (1) HK1200357A1 (da)
HR (1) HRP20170193T4 (da)
HU (1) HUE033342T2 (da)
LT (1) LT2753352T (da)
MX (1) MX350126B (da)
PL (1) PL2753352T5 (da)
PT (1) PT2753352T (da)
RS (1) RS55707B2 (da)
SI (1) SI2753352T2 (da)
WO (1) WO2012028741A1 (da)
ZA (1) ZA201400610B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014004896B1 (pt) 2010-09-03 2023-02-14 Valneva Usa, Inc. Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
ES2615737T3 (es) * 2011-05-27 2017-06-08 Glaxosmithkline Biologicals S.A. Composición inmunogénica
AU2016203241B2 (en) * 2011-05-27 2018-05-10 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SI2928489T1 (sl) * 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
ES2870506T3 (es) * 2015-02-19 2021-10-27 Immune Biosolutions Inc Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
CA3014498A1 (en) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
JP7426953B2 (ja) 2018-06-19 2024-02-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP3931217A1 (en) * 2019-02-25 2022-01-05 PreviPharma Consulting GmbH Epitopes of clostridium difficile toxins a and b and uses thereof
WO2021205017A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
ATE366312T1 (de) * 1994-10-24 2007-07-15 Ophidian Pharm Inc Impfstoff und antitoxine zur behandlung und vorbeugung von c. difficile krankheiten
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
JPH11509200A (ja) 1995-07-07 1999-08-17 オラバックス インク． 粘膜アジュバントとしてのクロストリジウム・ディフィシール（Ｃｌｏｓｔｒｉｄｉｕｍ Ｄｉｆｆｉｃｉｌｅ）トキシン
CA2267523A1 (en) 1996-10-04 1998-04-09 Auckland Uniservices Limited Regulation of neural enzymes
EP0952850A2 (en) 1996-12-31 1999-11-03 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
ES2288555T3 (es) 2001-05-21 2008-01-16 Intercell Ag Moleculas de oligodesoxinucleotidos inmunoestimuladores.
WO2003047602A1 (en) 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
PL1766093T3 (pl) * 2004-02-06 2011-11-30 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
DE602005025977D1 (de) 2004-08-23 2011-03-03 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CA2693958A1 (en) * 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
JP5965389B2 (ja) 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
BR112014004896B1 (pt) 2010-09-03 2023-02-14 Valneva Usa, Inc. Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo
JP5917682B2 (ja) * 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
ES2615737T3 (es) 2011-05-27 2017-06-08 Glaxosmithkline Biologicals S.A. Composición inmunogénica
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
SI2928489T1 (sl) 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

Also Published As

Publication number Publication date
HK1200357A1 (en) 2015-08-07
US9598472B2 (en) 2017-03-21
CN103957931A (zh) 2014-07-30
RS55707B1 (sr) 2017-07-31
MX350126B (es) 2017-08-28
US10821166B2 (en) 2020-11-03
CA2873272A1 (en) 2012-03-08
KR101907434B1 (ko) 2018-10-12
AU2011298306A1 (en) 2014-02-20
CA2873272C (en) 2020-10-27
WO2012028741A1 (en) 2012-03-08
SI2753352T2 (sl) 2022-10-28
US20210393761A1 (en) 2021-12-23
CN103957931B (zh) 2017-10-24
EP2753352B2 (en) 2022-08-10
EP3167899A1 (en) 2017-05-17
AU2011298306B2 (en) 2017-10-19
US20230173052A1 (en) 2023-06-08
KR20140057315A (ko) 2014-05-12
US10357557B2 (en) 2019-07-23
ES2631032T5 (es) 2022-10-26
RS55707B2 (sr) 2022-10-31
EP3895728A1 (en) 2021-10-20
JP6121421B2 (ja) 2017-04-26
BR112014004896B1 (pt) 2023-02-14
JP2014525249A (ja) 2014-09-29
MX2014002595A (es) 2014-10-13
PL2753352T3 (pl) 2017-07-31
US11357844B2 (en) 2022-06-14
LT2753352T (lt) 2017-05-25
ES2867375T3 (es) 2021-10-20
PT2753352T (pt) 2017-03-08
DK2753352T3 (da) 2017-03-06
PL2753352T5 (pl) 2022-10-17
ZA201400610B (en) 2015-09-30
US20170239340A1 (en) 2017-08-24
HRP20170193T4 (hr) 2022-09-02
SI2753352T1 (sl) 2017-06-30
ES2631032T3 (es) 2017-08-25
US20210121554A1 (en) 2021-04-29
US11478540B2 (en) 2022-10-25
DK2753352T5 (da) 2017-05-01
EP2753352A1 (en) 2014-07-16
CY1118664T1 (el) 2017-07-12
EP2753352B1 (en) 2017-01-25
EP3167899B1 (en) 2021-03-24
US20150056238A1 (en) 2015-02-26
HRP20170193T1 (hr) 2017-06-02
HUE033342T2 (en) 2017-11-28
US20190290747A1 (en) 2019-09-26
BR112014004896A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
DK2753352T4 (da) Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
LTPA2019012I1 (lt) Plazmos kalikreiną surišantys baltymai
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
DK3130347T3 (da) PH20-polypeptidvarianter, formuleringer og anvendelser deraf
DK2542590T4 (da) Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
CO7020851A2 (es) Proteínas y péptidos modificados
DK2638173T3 (da) Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf
DK2728002T3 (da) Heterodimeriseret polypeptid
DK3495392T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
EP2709603A4 (en) MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS AND APPLICATIONS THEREWITH
DK3572091T3 (da) Modificerede relaxinpolypeptider og anvendelser deraf
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
DK2552434T3 (da) Peptider og anvendelse deraf
DK2538666T3 (da) Fjernstyringsterminal og informationsbehandlingsapparat
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK2729160T3 (da) Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
DK2555789T3 (da) Hæmmende peptider afledt af trem-lignende transcript 1 (tlt-1) og anvendelser deraf
DK2705144T4 (da) Polypeptid
DK2782598T3 (da) Rekombinante proteiner og terapeutiske anvendelser deraf
DK2545168T3 (da) Modificerede cellulaser fra familie 5 og anvendelser deraf
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
DK3010535T3 (da) Toxoide peptider afledt fra fenol opløselige modulin, delta toxin, superantigener og fusioner deraf
DK2855676T3 (da) SAMMENSÆTNINGER OG FREMGANGSMÅDER TIL PEPTIDEKSPRESSION OG -OPRENSNING UNDER ANVENDELSE AF ET TYPE lll-SEKRETIONSSYSTEM
EP2747773A4 (en) METHODS AND COMPOSITIONS COMPRISING A PEPTIDE DERIVED FROM THE B-TERMINAL END OF BAX